Ginkgo Bioworks Holdings financials
$11.96+14.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $19.5M | $33.4M | $38.8M | $39.1M | $38.2M | $43.8M | $89.0M | $56.2M | $37.9M | $34.8M | $55.4M |
| Gross profit | $18.4M | $16.4M | $26.1M | $26.0M | $33.8M | $34.1M | $34.2M | $77.0M | $42.5M | $28.7M | $28.1M | $48.5M |
| Gross margin | 91.5% | 84.1% | 78.1% | 67.0% | 86.3% | 89.3% | 78.1% | 86.5% | 75.6% | 75.7% | 81.0% | 87.5% |
| Operating income | -$58.5M | -$78.5M | -$70.8M | -$90.0M | -$58.2M | -$85.6M | -$103.6M | -$55.2M | -$222.9M | -$178.0M | -$115.3M | -$286.4M |
| Net income | -$46.7M | -$82.6M | -$80.8M | -$80.8M | -$60.3M | -$91.0M | -$107.5M | -$56.4M | -$217.2M | -$165.9M | -$211.7M | -$302.9M |
| Net margin | −231.7% | −424.1% | −241.8% | −207.9% | −154.1% | −237.9% | −245.2% | −63.3% | −386.4% | −437.3% | −609.1% | −546.4% |
| Diluted EPS | $-0.75 | $-1.39 | $-1.41 | $-1.45 | $-1.10 | $-1.68 | $-2.00 | $-1.08 | $-4.23 | $-3.32 | $-2.18 | $-6.21 |
| EBITDA | -$46.2M | -$65.7M | -$56.4M | -$74.1M | -$39.3M | -$66.3M | -$83.8M | -$35.1M | -$140.7M | -$165.1M | -$156.1M | -$169.1M |
| Operating cash flow | -$44.3M | -$46.7M | -$47.7M | -$31.6M | -$40.3M | -$51.5M | -$42.4M | -$103.5M | -$84.4M | -$89.3M | -$57.8M | -$65.1M |
| Free cash flow | -$46.9M | -$48.6M | -$47.7M | -$31.6M | -$40.3M | -$59.1M | -$56.1M | -$118.6M | -$111.4M | -$96.0M | -$61.3M | -$69.5M |
| Diluted shares | 62.1M | 59.6M | 57.1M | 55.6M | 54.9M | 54.2M | 53.8M | 52.2M | 51.4M | 50.1M | 97.0M | 48.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.5M | $143.9M | $167.2M | $111.1M | $203.6M | $312.4M |
| Short-term investments | $217.6M | $229.6M | $255.4M | $350.8M | $270.1M | $204.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $990.0M | $1.03B | $1.12B | $1.19B | $1.23B | $1.29B |
| Total liabilities | $569.8M | $589.9M | $611.1M | $629.4M | $618.1M | $646.0M |
| Shareholders' equity | $420.3M | $443.2M | $508.6M | $559.8M | $613.0M | $647.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology